Sanofi

Equities

SAN

FR0000120578

Pharmaceuticals

Real-time Euronext Paris 09:10:05 2024-04-25 am EDT 5-day change 1st Jan Change
90.92 EUR +3.67% Intraday chart for Sanofi +6.84% +1.45%

This article is for Premium subscribers only

Signed up already?

Log In

Not subscribed yet?

Subscribe
SANOFI : Sanofi’s healthy Q1 performance hailed by markets Alphavalue
Sanofi Q1 Earnings Fall, Net Sales Climb MT
CAC40: down slightly on an avalanche of results CF
European Midday Briefing : Mood Cautious Ahead of More U.S Tech, Key Data DJ
Sanofi: quarterly EPS down by more than 7% at TCC CF
Wall Street: a note of weakness ahead of US GDP figures CF
Sanofi Posts Lower Q1 Net Income; Net Sales Up MT
Sanofi Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Sanofi Sales, Profit Beat Expectations DJ
Sanofi Q1 profit slips on generic competition, forex effects RE
EMEA Morning Briefing : Shares Seen Lower; Earnings, U.S. GDP Data in Focus DJ
SANOFI : Bernstein remains its Buy rating ZD
Sanofi to Enlist Banks for $20 Billion Consumer-health Spinoff MT
Sector Update: Health Care Stocks Rise Late Afternoon MT
Sector Update: Health Care MT
Sanofi Asks Banks to Pitch for Roles on Separation of Consumer Health Care Business MT
Sanofi Is Said To Ask Banks To Pitch For $20 Billion OTC Spinoff - Bloomberg News RE
CAC40: up sharply, back over 8100 pts CF
CAC40: back to 8100, E-Stoxx to 5000, Nasdaq +1.5 CF
CAC40: closes in on 8,100, well supported by W-Street CF
CAC40: up slightly after encouraging PMI figures CF
Sanofi: positive phase III data in IPT CF
Sanofi Reports Positive Results from Phase 3 Trial of Rilzabrutinib for Immune Thrombocytopenia MT
Sanofi Says Blood-Disorder Drug Meets Key Target in Late-Stage Trial DJ
Sanofi Reaches $100 Million Settlement for US Lawsuits Over Zantac Cancer Claims MT
Chart Sanofi
More charts
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (70.6%): prescription drugs in the areas of specialty medicine (59.3% of net sales; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases) and general medicine (40.7%; mainly for the treatment of diabetes and cardiovascular diseases); - human vaccines (17.4%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas; - consumer health products (12%). At the end of 2023, the group had 54 production sites throughout the world. Net sales are distributed geographically as follows: France (5.5%), Europe (18.6%), the United States (43%), North America (1.6%) and other (31.3%).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
87.7 EUR
Average target price
107.8 EUR
Spread / Average Target
+22.87%
Consensus